With KOSPI Breaking 5,000, Target Prices Raised for 66% of Listed Firms This Year... Hyundai Motor Tops the List

According to financial information provider FnGuide on the 17th, among 280 stocks for which at least three brokerages had presented target prices as of the 9th, 185 saw their targets revised upward compared with the end of last year. This accounts for 66% of the total.
Target prices were revised downward for 75 stocks, or 27% of the total. The remaining 20 stocks, or 7%, maintained the same target levels as before.
The fact that target price hikes outnumbered cuts is largely attributed to the overall strength of the market, with KOSPI breaking through the 5,000 level for the first time this year. Hyundai Motor recorded the largest increase in target price.
Its average target price jumped 86%, from 3,509,620 won at the end of last year to 6,542,310 won this month. Expectations grew after Hyundai Motor Group unveiled its next-generation humanoid robot "Atlas" and laid out its artificial intelligence (AI) robotics strategy at the Consumer Electronics Show 2026 (CES 2026) in January, which boosted related momentum.
Kang Sung-jin, a researcher at KB Securities, said, "Hyundai Motor Group is leading the robotics field in terms of mechanical completeness, simulation and training capabilities, commercialization strategy, and mass-production strategy," adding, "Despite this, its market capitalization is only one-twentieth that of Tesla, leaving it significantly undervalued. " The stock with the second-largest upward revision was also a Hyundai Motor Group affiliate, Hyundai AutoEver.
Hyundai AutoEver’s target price rose 81% this year, from 2,545,830 won to 4,610,000 won, marking the second-largest increase. The gain reflects expectations that the company will benefit if Hyundai Motor Group expands capital expenditure on robot-related facilities.
SeAH Besteel Holdings ranked third. Its target price was raised 74%, from 409,230 won to 710,630 won, on expectations that its U.
S. specialty alloy subsidiary will benefit as U.
S. space company SpaceX prepares for an Initial Public Offering (IPO).
They were followed by Hyosung TNC (up 64%), Satrec I (63%), ISC (62%), RFHIC (60%), and SK hynix (56%), in terms of the magnitude of target price increases. By contrast, PharmaResearch saw the steepest decline in average target price this year.
4%, from 7,170,000 won at the end of last year to 6,208,330 won this month, as slower growth in the domestic medical device market delayed its earnings recovery.
According to financial information provider FnGuide on the 17th, among 280 stocks for which at least three brokerages had presented target prices as of the 9th, 185 saw their targets revised upward compared with the end of last year. This accounts for 66% of the total.
jiany@fnnews.com Yeon Ji-an Reporter